RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address high unmet medical needs. We believe that we are well positioned to compete successfully using our RNAi technology platform for the development of novel therapeutics to improve patients’ lives. The Company is supported by a proven and experienced management team, an accomplished Scientific Advisory Board and an extensive intellectual property portfolio.
PROPRIETARY SELF-DELIVERING RNAi (sd-rxRNA®) TECHNOLOGY PLATFORM
Provided by Nasdaq.
May 16 - May 19, 2018International Investigative Dermatology (IID) Conference
Mar 27, 2018 at 10:00 AM EDTLandmark Venture Forum hosted by Landmark Angels
Mar 26, 2018 at 5:00 PM EDTRXi Pharmaceuticals Fourth Quarter and Year End 2017 Conference Call